ctx112
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2023 (NCT05643742)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, B-Cell · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Lupus Erythematosus, Systemic · Phase 1
- Lupus Nephritis · Phase 1
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Myositis · Phase 1
- Scleroderma, Diffuse · Phase 1
- Scleroderma, Systemic · Phase 1
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06925542 | Phase 1 | Mar 10, 2025 | CRISPR Therapeutics |
| NCT05643742 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | CRISPR Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CRISPR Therapeutics | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1